Kinetics and seroprevalence of SARS-CoV-2 antibodies – a comparison of 3 different assays

Purpose: Comparing seroprevalence and antibody kinetics in three different commercially available assays for SARS-CoV-2. Methods: : Serostatus of COVID-19 patients was analyzed 5 months and 10 months after their infection, using three different assays: Diasorin LIAISON®, Euroimmun®, Abbott Diagnostics® ARCHITECT. Results: : Seropositivity at baseline differed significantly depending on the assay (Diasorin 81%, Euroimmun 83%, Abbott 59%). At follow-up antibody levels detected in the Diasorin assay were stable, while there was a significant loss in seropositivity in the Euroimmun and Abbott assays. Conclusion: There are significant differences in SARS-CoV-2 antibody kinetics based on the specific assay used. Trial registration number, date of registration DRKS00022549, 29.07.2020 “retrospectively registered”